[SGLT2 inhibitors in heart failure]

Bonavento L, Alcaraz A, Alfie V, Argento F, Klappenbach R, Bardach A, Ciapponi A, Garcia Marti S, Augustovski F, Pichon Riviere A
Record ID 32018002317
Original Title: Inhibidores de SGLT2 para insuficiencia cardíaca
Authors' recommendations: High-quality evidence shows that adding SGLT2 inhibitors to standard optimized treatment for heart failure, mainly in patients with decreased left ventricle ejection fraction under 40%, significantly reduces cardiovascular mortality, hospitalizations due to heart failure and hospitalization times when compared with placebo. These results were consistent both in diabetic and non-diabetic patients. Low-quality evidence, obtained from indirect comparisons, suggests that adding SGLT2 inhibitors to the standard optimized treatment for heart failure in patients with a left ventricle ejection fraction lower under 40%, would be, at least, as effective as adding sacubitril/valsartan in reducing cardiovascular mortality and hospitalizations due to heart failure. The clinical practice guidelines assessed recommend adding it to standard treatment, both in diabetic and non-diabetic patients with an ejection fraction under 40% (Argentine Society of Cardiology, Argentine Federation of Cardiology, American College of Cardiology, Canadian Cardiovascular Society. Public health funders from Canada and the United Kingdom cover SGLT2 inhibitors in patients with symptomatic heart failure with decreased left ventricle ejection fraction, while public funders from Brazil, Germany and some United States private funders just cover it in Type 2 diabetes patients. No cost-effectiveness or budget impact studies have been found in Argentina. Dapaglifozin proved to be cost-effective in high-income countries such as the United Kingdom, Germany, Spain, Australia as well as in China and Thailand. Empaglifozin proved to be cos-effective in the United Kingdom.
Project Status: Completed
Year Published: 2021
English language abstract: An English language summary is available
Publication Type: Not Assigned
Country: Argentina
MeSH Terms
  • Heart Failure
  • Diabetes Mellitus, Type 2
  • Hypoglycemic Agents
  • Sodium-Glucose Transporter 2 Inhibitors
Organisation Name: Institute for Clinical Effectiveness and Health Policy
Contact Address: Dr. Emilio Ravignani 2024, Buenos Aires - Argentina, C1414 CABA
Contact Name: info@iecs.org.ar
Contact Email: info@iecs.org.ar
Copyright: Institute for Clinical Effectiveness and Health Policy (IECS)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.